Literature DB >> 9736577

Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice.

E W van Etten1, S V Snijders, W van Vianen, I A Bakker-Woudenberg.   

Abstract

In leukopenic mice with severe systemic candidiasis, single-dose treatment (5 mg of amphotericin B [AMB]/kg of body weight) with long-circulating polyethylene glycol-coated AMB liposomes (PEG-AMB-LIP) resulted in zero mortality and a significant reduction in the number of viable Candida albicans in the kidney, whereas 70% mortality was seen in mice treated with five daily doses of AmBisome (5 mg of AMB/kg . day). When the first of five daily doses of AmBisome was combined with a single low dose of Fungizone (0.1 mg of AMB/kg), the efficacy was equal to that of PEG-AMB-LIP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736577      PMCID: PMC105847     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue.

Authors:  I A Bakker-Woudenberg; M T ten Kate; L E Stearne-Cullen; M C Woodle
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

2.  Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.

Authors:  P Legrand; M Chéron; L Leroy; J Bolard
Journal:  J Drug Target       Date:  1997       Impact factor: 5.121

Review 3.  The use of lipid formulations of amphotericin B for systemic fungal infections.

Authors:  A C Leenders; S de Marie
Journal:  Leukemia       Date:  1996-10       Impact factor: 11.528

4.  Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.

Authors:  E W van Etten; C van den Heuvel-de Groot; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

5.  Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.

Authors:  E W van Etten; M T ten Kate; L E Stearne; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue.

Authors:  I A Bakker-Woudenberg; A F Lokerse; M T ten Kate; J W Mouton; M C Woodle; G Storm
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

  6 in total
  6 in total

1.  Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.

Authors:  E W Van Etten; L E Stearne-Cullen; M ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid.

Authors:  Hong Li; Yanhui Lu; Longzhu Piao; Jun Wu; Shujun Liu; Guido Marcucci; Manohar Ratnam; Robert J Lee
Journal:  Int J Pharm       Date:  2010-09-29       Impact factor: 5.875

3.  Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Authors:  T J Walsh; J L Goodman; P Pappas; I Bekersky; D N Buell; M Roden; J Barrett; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 4.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.

Authors:  Paul O Gubbins; Jarrett R Amsden; Scott A McConnell; Elias J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

Review 6.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.